Login
Navigate Fool.com
Will SNSS beat
the market?
Community Rating: 2 Stars: Unattractive

6.70 0.32 (5.02%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $6.33
Previous Close $6.38
Daily Range $6.25 - $6.73
52-Week Range $3.84 - $7.49
Market Cap $403.5M
P/E Ratio -9.25
Dividend (Yield) $0.00 (0.0%)
Volume 629,116
Average Daily Volume 509,619
Current FY EPS -$0.76

How do you think SNSS
will perform against the market?

Top SNSS Bull/Bear Pitches

 

akshara3000 (0)
Submitted January 5, 2011

If phase 3 trial info is released midterm through the study, and it is as positive and consistent as previous results, the stock will jump remarkably, especially after being beaten down so badly since … More

0 Replies Reply Report this Post
 

zzlangerhans (< 20)
Submitted June 13, 2014

Sunesis is still oddly volatile and out of sync with the small cap biotech segment ahead of VALOR unblinding, now pushed back to the end of Q3 or early Q4. This data has been delayed so many times I'v … More

0 Replies Reply Report this Post

News & Commentary

Better Buy: Clovis Oncology vs. Sunesis Pharmaceuticals

Clovis Oncology and Sunesis Pharmaceuticals are facing pivotal catalysts for their experimental cancer drugs. Which company offers the better risk-to-reward ratio?

Is Sunesis Pharmaceuticals Poised for a Breakout?

The little-known biopharma Sunesis Pharmaceuticals is on the cusp of unblinding late-stage trial data for its flagship oncology drug vosaroxin. Leading into this seminal event, management sounds fairly confident of a positive result, but the market clearly has its doubts. Why?

3 Ways Ariad Pharmaceuticals Could Mount a Comeback

Ariad Pharmaceuticals has been one of the worst-performing stocks across all sectors in the past year. Can this struggling oncology company make a comeback?

2 Biotech Stocks to Watch: Merrimack Pharmaceuticals and Sunesis Pharmaceuticals

Two clinical-stage cancer companies could provide market-beating returns for risk-tolerant investors.

Mid-Morning Market Update: Markets Drop; Family Dollar Plans To Close 370 Stores

Is Now the Time to Invest in Agios Pharmaceuticals, Inc?

Agios Pharmaceuticals reported surprisingly strong results for an early stage blood cancer drug candidate today. Should you dig deeper into this story?

Tuesday Sector Leaders: Biotechnology, Apparel Stores

3 Small Cap Biotechs Developing Novel Cancer Treatments

Three biotechs with pending clinical catalysts for their experimental cancer treatments.

3 Horrendous Health-Care Stocks This Week

Canceled clinical studies. Disappointing earnings. Double-digit declines. These three stocks had truly horrendous weeks.

Why Sunesis Pharmaceuticals, Inc. Shares Slipped

Is this meaningful or just another movement?

See More SNSS News...

Sector

Healthcare

Industry

Drugs

Sunesis Pharmaceuticals, Inc. (SNSS) Description

The Company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs. Website: http://www.sunesis.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks